Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions
Open Access
- 1 December 2023
- journal article
- review article
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 16, 249-276
Abstract
Crohn’s disease is a complex, relapsing and remitting inflammatory disorder of the gastrointestinal tract with a variable disease course. While the treatment options for Crohn’s disease have dramatically increased over the past two decades, predicting individual patient response to treatment remains a challenge. As a result, patients often cycle through multiple different therapies before finding an effective treatment which can lead to disease complications, increased costs, and decreased quality of life. Recently, there has been increased emphasis on personalized medicine in Crohn’s disease to identify individual patients who require early advanced therapy to prevent complications of their disease. In this review, we summarize our current approach to management of Crohn’s disease by identifying risk factors for severe or disabling disease and tailoring individual treatments to patient-specific goals. Lastly, we outline our knowledge gaps in implementing personalized Crohn’s disease treatment and describe the future directions in precision medicine.Keywords
This publication has 237 references indexed in Scilit:
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2012
- Biomarkers in inflammatory bowel disease: current practices and recent advancesTranslational Research, 2012
- Factors affecting outcomes in Crohn's disease over 15 yearsGut, 2012
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- Aminosalicylates for induction of remission or response in Crohn's disease2010
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortGastroenterology, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Adalimumab for the treatment of fistulas in patients with Crohn’s diseaseGut, 2009
- Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexesBMC Research Notes, 2009
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007